Pulmonary Arterial Hypertension-Group 1: What the Primary Care NP Needs to Know

Start Date: 04/01/21 **End Date:** 04/30/2022

Program goal: NPs in primary care settings will obtain the knowledge to describe disease pathology, recognize symptoms of PAH, coordinate testing and diagnosis and initiate timely referral to PAH care center.

Format:

- Two online "live" webinars
- An on-demand web-based enduring activity
- A downloadable patient/provider tool



Learning Objectives:

- Describe underlying disease pathology associated with PAH Group 1
- Summarize key symptoms associated with PAH
- List evidence-based measures used to establish a diagnosis of PAH
- Identify when patients should be referred to PAH specialty centers
- Describe current evidence-based strategies used to manage PAH

Participation *(624 Web 1, 396 Web 2, 6,450 Enduring) **(75 Web 1, 27 Web 2, 3,028 Enduring

Unique Learners	NP	Nurse / NP student	Other APRN / Other
Registrations 7,470*	89.2%	7.7%	2% (53) /
Completions 3,128**	(2,789)	(242)	3.1% (42)

Family	Adult / Gerontology	Acute Care	Other
56.1% (1754)	19% (594)	13.1% (411)	11.8% (369)

Practice setting

Family / Primary care	Cardiology	Acute care	Inpatient or Hospital / IM	Other / N/A-do not provide direct patient care
26.6%	13%	9%	5.7% (178) /	35.4% (1109) /
(832)	(408)	(295)	4.3% (135)	5.5% (171)

Faculty Progressive Med **Pre- to Post-Activity** risks Gains Steps to **EKG** Median Manage **Finding** survival Differential Vaccine Diagnoses Susan McDevitt, Martha Kingman, **Associated** MSN, ACNP-BC DNP, FNP-C conditions **Knowledge** Management **Strategies Increased Establish** diagnosis Assess **Key Takeaways** 43% **PH Risk** Overall increase in mean percent correct answers Collaborate with (10 questions, P < 0.001) **Confidence Specialist Targeted** Increased **ECHO** drug therapy 50% Screen Early Recognize "Extremely or Very Confident" symptoms (4/5 or 5/5 on Likert scale) **Practice** 48% **Initiate** Change early Average of PAH referral Center 1-5 Years in 87% Referral AP role Commitment Refer **Perceived Distance** (3.48/4 on Likert scale) Sooner **Barriers** to Care Approved for 1.25 Drug contact hours or CE of Cost or which 0.5 of which may **Approval** Time be applied to Rx Sponsored by an independent Specialty educational grant from Actelion

(n=3,128 based on number of learners who completed pre-, post- and program evaluations)